MENU
MDXG
AS OF
Feb 4, 04:59 PM (EDT)
Price
$5.10
Change
+$0.13 (+2.62%)
Capitalization
737.55M
28 days until earnings call
Intraday BUY SELL Signals
+Compare
MDXG
Stock ticker: NASDAQ
AS OF
Feb 4, 04:59 PM (EDT)
Price
$5.10
Change
+$0.13 (+2.62%)
Capitalization
737.55M

MDXG MiMedx Group Forecast, Technical & Fundamental Analysis

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone... Show more

Industry: #Biotechnology
MDXG
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for MDXG with price predictions
Feb 03, 2026

MDXG in downward trend: 10-day moving average moved below 50-day moving average on December 30, 2025

The 10-day moving average for MDXG crossed bearishly below the 50-day moving average on December 30, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 26, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on MDXG as a result. In of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for MDXG turned negative on December 26, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at .

MDXG moved below its 50-day moving average on December 26, 2025 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for MDXG moved below the 200-day moving average on January 20, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDXG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for MDXG entered a downward trend on February 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MDXG advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .

MDXG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.086) is normal, around the industry mean (27.519). P/E Ratio (18.444) is within average values for comparable stocks, (51.491). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.893). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (1.893) is also within normal values, averaging (331.843).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MDXG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
MDXG
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

MDXG is expected to report earnings to fall 39.73% to 9 cents per share on March 04

MiMedx Group MDXG Stock Earnings Reports
Q4'25
Est.
$0.09
Q3'25
Beat
by $0.09
Q2'25
Beat
by $0.05
Q1'25
Est.
$0.06
Q4'24
Beat
by $0.01
The last earnings report on October 29 showed earnings per share of 15 cents, beating the estimate of 5 cents. With 454.99K shares outstanding, the current market capitalization sits at 737.55M.
A.I. Advisor
published General Information

General Information

a manufacturer of patent protected regenerative biomaterial products and bioimplants

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1775 West Oak Commons Court, NE
Phone
+1 770 651-9100
Employees
895
Web
https://www.mimedx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CHDVX13.840.11
+0.80%
Cullen High Dividend Equity I
VVOCX22.070.02
+0.09%
Invesco Value Opportunities C
MXEOX12.96N/A
N/A
Empower Emerging Markets Equity Inv
CSPIX13.41-0.05
-0.37%
Calvert Global Small-Cap Equity I
ARIGX14.22-0.27
-1.86%
Aristotle Growth Equity I

MDXG and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MDXG has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MDXG jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDXG
1D Price
Change %
MDXG100%
-2.36%
AXON - MDXG
47%
Loosely correlated
-1.89%
VCYT - MDXG
42%
Loosely correlated
-1.10%
ARRY - MDXG
39%
Loosely correlated
+1.71%
RAPT - MDXG
38%
Loosely correlated
+0.12%
INM - MDXG
38%
Loosely correlated
-3.64%
More